Pyxis Oncology (PYXS) Other Accumulated Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Other Accumulated Expenses data on file, last reported at $4.0 million in Q4 2025.

• On a quarterly basis, Other Accumulated Expenses fell 37.2% year-over-year to $4.0 million in Q4 2025; TTM through Dec 2025 was $4.0 million, a 37.2% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, down 37.2% from the prior year.
• Other Accumulated Expenses for Q4 2025 stood at $4.0 million, down from $6.4 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for PYXS reached as high as $17.4 million in Q4 2022 and fell as low as $356000.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $6.1 million across 5 years, with a median of $4.0 million in 2025.
• Across the five-year window, Other Accumulated Expenses slumped 97.96% in 2023 and jumped 1687.92% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $2.4 million in 2021, then surged by 631.37% to $17.4 million in 2022, then slumped by 97.96% to $356000.0 in 2023, then soared by 1687.92% to $6.4 million in 2024, then slumped by 37.2% to $4.0 million in 2025.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $4.0 million in Q4 2025, $6.4 million in Q4 2024, and $356000.0 in Q4 2023.